{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:49:11Z","timestamp":1790938151534,"version":"4.1.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-CA008748"],"award-info":[{"award-number":["P30-CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"publisher","award":["R35 NS105109-01"],"award-info":[{"award-number":["R35 NS105109-01"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cycle for Survival Equinox Innovation Award"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>High-dose methotrexate-based chemotherapy is the mainstay of treatment of primary central nervous system lymphoma (PCNSL). Only \u223c60% of patients achieve a complete response to first-line therapy with frequent relapses. The Bruton\u2019s tyrosine kinase inhibitor ibrutinib has shown promising antitumor activity in recurrent\/refractory PCNSL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The goal of the current single-center phase 2 trial was to explore whether the addition of ibrutinib to the combination of rituximab, methotrexate, procarbazine, and vincristine (R-MVP\/i) increases complete response rate (CCR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty newly diagnosed PCNSLs were enrolled; median age 69 (range 41-79), median Eastern Cooperative Oncology Group (ECOG)\u2009=\u20091. Twenty-nine patients completed R-MVP\/i, 1 withdrew consent after 2 cycles. A complete response (CR)\/complete response unconfirmed (CRu) was achieved in 29 patients and a partial response in 1 for a CRR of 29\/30 (97%, 95% CI: 83.3%, 99.8%). Treatment was well tolerated with no grade 5 toxicity observed. Eight patients experienced 13 grade 4 toxicities (lymphopenia [n\u2009=\u20093], neutropenia [n\u2009=\u20094], thrombocytopenia [n\u2009=\u20093], and white cell count decrease [n\u2009=\u20093]). The most common toxicities were thrombocytopenia, anemia, lymphopenia, and liver enzyme elevations. No Aspergillus or Pneumocystis infections occurred. No refractory disease was observed. For the 29 patients completing the trial, 19 received consolidation with cytarabine (Ara-C), 8 autologous stem cell transplant, 1 rituximab maintenance, and 1 was observed without maintenance or consolidation. At a median follow-up of 25.1 months (range 3.3-49.2), the median progression-free (PFS) and overall survival were not reached with a 2-year PFS of 84.2% (95% CI: 62.7%-93.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>R-MVP\/i was well tolerated and associated with excellent disease control and survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/neuonc\/noag011","type":"journal-article","created":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T12:37:58Z","timestamp":1768567078000},"page":"1277-1285","source":"Crossref","is-referenced-by-count":3,"title":["Ibrutinib in combination with rituximab, methotrexate, vincristine, and procarbazine for newly diagnosed primary CNS lymphoma"],"prefix":"10.1093","volume":"28","author":[{"given":"Lauren R","family":"Schaff","sequence":"first","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5854-0251","authenticated-orcid":false,"given":"Elena","family":"Pentsova","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Malani","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Stone","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor T","family":"Gavrilovic","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Kaley","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Emadi-Paramkouhi","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerina","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Rodriguez","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josey","family":"Tobin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Kaluski","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-6112","authenticated-orcid":false,"given":"Anne S","family":"Reiner","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine S","family":"Panageas","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M","family":"DeAngelis","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine H","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Radiology, Memorial Sloan Kettering Cancer Center , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo K","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7485-0441","authenticated-orcid":false,"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer \u00adCenter , New York, New York,","place":["USA"]},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"key":"2026051916121004300_noag011-B1","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1200\/JCO.2017.72.7602","article-title":"Primary CNS lymphoma","volume":"35","author":"Grommes","year":"2017","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B2","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/0360-3016(92)90538-s","article-title":"Non-Hodgkin\u2019s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the radiation therapy oncology group (RTOG): RTOG 8315","volume":"23","author":"Nelson","year":"1992","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026051916121004300_noag011-B3","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1200\/JCO.1992.10.4.635","article-title":"Combined modality therapy for primary CNS lymphoma","volume":"10","author":"DeAngelis","year":"1992","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B4","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.1200\/JCO.2000.18.17.3144","article-title":"Treatment for primary CNS lymphoma: the next step","volume":"18","author":"Abrey","year":"2000","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B5","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1200\/JCO.2013.50.4910","article-title":"Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B6","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood"},{"key":"2026051916121004300_noag011-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/aol-22-19","article-title":"Is more better? Increased doses of high dose methotrexate and addition of rituximab is associated with improved outcomes in a large primary CNS lymphoma cohort","volume":"7","author":"Yerram","year":"2023","journal-title":"Ann Lymphoma"},{"key":"2026051916121004300_noag011-B8","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf221","article-title":"Multicenter randomized phase II study of R-MPV-A chemoimmunotherapy with or without low-dose whole-brain radiotherapy for newly-diagnosed primary CNS lymphoma","author":"Omuro","journal-title":"Neuro Oncol"},{"key":"2026051916121004300_noag011-B9","doi-asserted-by":"publisher","first-page":"e251","DOI":"10.1016\/S2352-3026(15)00074-5","article-title":"Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial","volume":"2","author":"Omuro","year":"2015","journal-title":"Lancet Haematol"},{"key":"2026051916121004300_noag011-B10","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1182\/blood.2020008377","article-title":"Primary central nervous system lymphoma","volume":"140","author":"Schaff","year":"2022","journal-title":"Blood"},{"key":"2026051916121004300_noag011-B11","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of Bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"key":"2026051916121004300_noag011-B12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2019.05.024","article-title":"Ibrutinib monotherapy for relapse or refractory primary CNS lymphoma and primary vitreoretinal lymphoma: final analysis of the phase II \u201cproof-of-concept\u201d iLOC study by the lymphoma study association (LYSA) and the French oculo-cerebral lymphoma (LOC) network","volume":"117","author":"Soussain","year":"2019","journal-title":"Eur J Cancer"},{"key":"2026051916121004300_noag011-B13","doi-asserted-by":"publisher","first-page":"4005","DOI":"10.1158\/1078-0432.CCR-24-0605","article-title":"A phase II study assessing long-term response to ibrutinib monotherapy in recurrent or refractory CNS lymphoma","volume":"30","author":"Grommes","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026051916121004300_noag011-B14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood"},{"key":"2026051916121004300_noag011-B15","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"2026051916121004300_noag011-B16","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1093\/neuonc\/noaa145","article-title":"Phase I\/II study of tirabrutinib, a second-generation Bruton\u2019s tyrosine kinase inhibitor, in relapsed\/refractory primary central nervous system lymphoma","volume":"23","author":"Narita","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026051916121004300_noag011-B17","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1200\/JCO.2025.43.16_suppl.2019","article-title":"Tirabrutinib for the treatment of relapsed or refractory primary central nervous system lymphoma: efficacy and safety from the phase II PROSPECT study","volume":"43","author":"Nayak","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B18","doi-asserted-by":"publisher","first-page":"5711","DOI":"10.1200\/JCO.2006.08.2941","article-title":"Primary Central nervous system lymphoma: the memorial Sloan-Kettering cancer center prognostic model","volume":"24","author":"Abrey","year":"2006","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B19","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"2026051916121004300_noag011-B20","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13045-024-01606-w","article-title":"Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB\/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary Central nervous system lymphoma (PCNSL) patients","volume":"17","author":"Alcantara","year":"2024","journal-title":"J Hematol Oncol"},{"key":"2026051916121004300_noag011-B21","doi-asserted-by":"publisher","first-page":"3692","DOI":"10.1200\/JCO.22.00491","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients age 60 years and younger: long-term results of the randomized phase II PRECIS study","volume":"40","author":"Houillier","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B22","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(16)00036-3","article-title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international extranodal lymphoma study group-32 (IELSG32) phase 2 trial","volume":"3","author":"Ferreri","year":"2016","journal-title":"Lancet Haematol"},{"key":"2026051916121004300_noag011-B23","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1182\/bloodadvances.2023011657","article-title":"Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of alliance 51101","volume":"8","author":"Batchelor","year":"2024","journal-title":"Blood Adv"},{"key":"2026051916121004300_noag011-B24","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1200\/JCO.2015.64.8634","article-title":"Phase I and II study of induction chemotherapy with methotrexate, rituximab, and temozolomide, followed by whole-brain radiotherapy and postirradiation temozolomide for primary CNS lymphoma: NRG oncology RTOG 0227","volume":"34","author":"Glass","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026051916121004300_noag011-B25","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S1470-2045(18)30747-2","article-title":"Rituximab in patients with primary CNS lymphoma (HOVON 105\/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study","volume":"20","author":"Bromberg","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noag011\/66483619\/noag011.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1277\/66483619\/noag011.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/28\/5\/1277\/66483619\/noag011.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T20:12:17Z","timestamp":1779221537000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/28\/5\/1277\/8431722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":25,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,1,20]]},"published-print":{"date-parts":[[2026,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noag011","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,1,20]]}}}